EXACT Sciences (EXAS) Now Covered by Goldman Sachs Group

Equities researchers at Goldman Sachs Group began coverage on shares of EXACT Sciences (NASDAQ:EXAS) in a report released on Monday, Marketbeat Ratings reports. The firm set a “neutral” rating and a $51.00 price target on the medical research company’s stock. Goldman Sachs Group’s price target suggests a potential upside of 2.33% from the stock’s previous close.

EXAS has been the subject of a number of other reports. Zacks Investment Research raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a report on Tuesday, January 16th. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. William Blair reissued a “buy” rating on shares of EXACT Sciences in a report on Wednesday, January 10th. Canaccord Genuity reissued a “buy” rating and issued a $60.00 target price (up from $45.00) on shares of EXACT Sciences in a report on Tuesday, October 3rd. Finally, Robert W. Baird reissued a “buy” rating and issued a $49.00 target price on shares of EXACT Sciences in a report on Friday, October 6th. Eight equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. EXACT Sciences presently has a consensus rating of “Buy” and a consensus price target of $52.84.

EXACT Sciences (EXAS) traded down $0.23 during mid-day trading on Monday, hitting $49.84. 1,951,663 shares of the company were exchanged, compared to its average volume of 3,958,540. EXACT Sciences has a 1 year low of $17.77 and a 1 year high of $63.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34. The stock has a market capitalization of $6,000.00, a price-to-earnings ratio of -43.34 and a beta of 0.68.

In related news, insider Kevin T. Conroy sold 110,439 shares of the firm’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $50.49, for a total value of $5,576,065.11. Following the completion of the sale, the insider now directly owns 940,491 shares in the company, valued at $47,485,390.59. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP D Scott Coward sold 1,665 shares of the firm’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $52.54, for a total value of $87,479.10. Following the completion of the sale, the senior vice president now owns 37,558 shares of the company’s stock, valued at $1,973,297.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 846,274 shares of company stock valued at $46,537,343. 4.00% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Krilogy Financial LLC lifted its position in shares of EXACT Sciences by 1,460.0% during the second quarter. Krilogy Financial LLC now owns 3,900 shares of the medical research company’s stock worth $138,000 after purchasing an additional 3,650 shares during the last quarter. Crow Point Partners LLC bought a new stake in shares of EXACT Sciences during the fourth quarter worth $145,000. Oppenheimer Asset Management Inc. lifted its position in shares of EXACT Sciences by 2,925.7% during the third quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock worth $150,000 after purchasing an additional 3,072 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of EXACT Sciences during the third quarter worth $183,000. Finally, Crescent Grove Advisors LLC bought a new stake in shares of EXACT Sciences during the third quarter worth $200,000. Institutional investors own 82.02% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “EXACT Sciences (EXAS) Now Covered by Goldman Sachs Group” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/29/exact-sciences-exas-now-covered-by-goldman-sachs-group.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply